Chu Montpellier-Hopital Saint-Eloi
Montpellier 34295
4 studies enrolling now · 11 studies all time
What they study most
B Cell Lymphoma, B-cell Malignancy, CLL, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hepatocellular Carcinoma (HCC), Inherited Mitochondrial Disease, Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation, MCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Studies at this site
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia — Recruiting now
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — Recruiting now
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. — Recruiting now
- Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
- Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories — Completed
- An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
- A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease — Completed
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed